Lukas Biomedical Inc. (TPEX: 6814)
Health Care · Biotechnology · TW
NT$22.30
-7.85% today · -12.9% 1Y
Lukas Biomedical Inc. (TPEX: 6814) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.33M and employs 87 people.
Over the last twelve months the share price has lost 12.9%, trading between 21.20 and 32.50.
Tweenvest scores Lukas Biomedical Inc. across four factors: quality 33/100, value 52/100, growth 0/100. Its strongest factor is value.
6814 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.33M
- Revenue (TTM)
- $5.34M
- P/E
- —
- EPS
- -2.19
- Dividend yield
- —
- Beta (5Y)
- 0.13
- 52-week high
- NT$32.50
- 52-week low
- NT$21.20
- Avg volume (3M)
- —
- Shares outstanding
- 41.87M
- Employees
- 87
- Next earnings
- —
About Lukas Biomedical Inc.
Founded in 2002 and headquartered in New Taipei, Taiwan, Lukas Biomedical Inc. primarily develops immune cell medical technologies. These innovations are utilized for regenerative medicine and as complementary treatments for cancer. The company's operations are segmented into four distinct areas: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. Furthermore, it diversifies its business by wholesaling and retailing cosmetics, alongside providing housing equipment rental services.
- ISIN
- TW0006814007
- Founded
- 2002
- Listed since
- Dec 31, 2020
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.16 | -0.14% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.53 | +0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.99 | +0.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $829.99 | +0.18% |
| argenx SEENXTBR: ARGX | $63.06B | €873.60 | +1.09% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.20 | +1.66% |
Figures last refreshed Aug 18, 2026.